All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

  TRANSLATE

The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The MPN Hub
Brought to you by Scientific Education Support

The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb and Incyte. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

EHA 2025 Abstracts: What’s hot in MPN?

By Jen Wyatt Green

Share:

Jun 9, 2025

Learning objective: After reading this article, learners will be able to cite a new clinical development in myeloproliferative neoplasms.

To help navigate the exciting content being presented at the 30th European Haematology Association (EHA) Congress, June 12–15, 2025, Milan, Italy the MPN Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in MPN.

EHA 2025: Top abstracts in MPN

Abstract #TitlePresenterDateTime (CEST)

 

Oral presentations

 
S220Hematological improvement and other clinical benefits of elritercept as monotherapy and in combination with ruxolitinib in participants with myelofibrosis (MF) from the ongoing phase 2 RESTORE trialTimothy DevosThursday, June 1217:00–17:15
S221Preliminary data from phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, showed clinical response correlating with cytokine modulation in patients with myelofibrosisLindsay ReinThursday, June 1217:15–17:30
S222Ropeginterferon alfa-2b for pre-fibrotic primary myelofibrosis and DIPSS low/intermediate-risk myelofibrosisHarry GillThursday, June 1217:30–17:45
S223Pelabresib in combination with ruxolitinib for Janus kinase inhibitor-naive patients with myelofibrosis: 72-week follow-up with long-term efficacy outcomes of the phase III MANIFEST-2 studyAlessandro VannucchiThursday, June 1217:45–18:00
S224SANRECO, an on-going phase1/2 study evaluating divesiran, a novel galnac-conjugated siRNA, in patients with polycythemia veraMarina KremyanskayaThursday, June 1218:00–18:15
S215Clinical characteristics and survival of 312 patients with MPL-mutant essential thrombocythemia: An international European leukemianet collaborative studySteffen KoschmiederFriday, June 1317:00–17:15
S216The revised mutation-adjusted risk score (MARS-r) for predicting overall survival in patients with advanced systemic mastocytosis treated with midostaurin or avapritinibJohannes LübkeFriday, June 1317:15–17:30
S217Neutrophil-to lymphocyte ratio as a surrogate inflammatory biomarker for JAK2V617F suppression and event-free survival in polycythemia veraTiziano BarbuiFriday, June 1317:30–17:45
S218Clinical outcomes in patients with myelofibrosis treated with ruxolitinib and anemia supporting medicationsPankit VachhaniFriday, June 1317:45–18:00
S219Genomic profiling for clinical decision making in post-polycythemia vera and post-essential thrombocythemia myelofibrosisBarbara MoraFriday, June 1318:00–18:15
S102Better safety and efficacy with ropeginterferon alfa-2b over anagrelide as second-line treatment of essential thrombocythemia in the topline results of the randomized phase 3 SURPASS-ET trialHarry GillSaturday, June 1412:15–12:30
S210Robust mouse model of secondary acute myeloid leukemia: Revealing key role of TP53 mutations and persistent STAT5 activation.Stefan ConstantinescuSunday, June 1511:00–11:15
S212INCA035784, a novel, equipotent T cell-redirecting antibody for patients with myeloproliferative neoplasms carrying different types of calreticulin mutationsBeth PsailaSunday, June 1511:30–11:45
LB4002INCA33989 is a novel, first in class, mutant calreticulin-specific monoclonal antibody that demonstrates safety and efficacy in patients with essential thrombocythemia (ET)John MascarenhasSunday, June 1509:15–10:45

 

Posters

 
PF828Survival impact and kinetics of hemoglobin improvement with momelotinib in patients with myelofibrosis and moderate to severe anemia: Post hoc analyses of SIMPLIFY-1 and MOMENTUMFrancesca PalandriFriday, June 1318:30–19:30
PF825TYK2 is specifically activated in CALR-mutant myeloproliferative neoplasms and JAK2 expression determines its druggabilityNicolas ChatainFriday, June 1318:30–19:30
PS1841Relationship between hemoglobin and quality of life in non-transfusion-dependent patients with myelofibrosis treated with luspaterceptHaifa Kathrin Al-AliSaturday, June 1418:30–19:30
PS1847Deep molecular responses with low-fixed dose of ropeginterferon alfa-2b in a rollover cohort of the LOW-PV trialTiziano BarbuiSaturday, June 1418:30–19:30
PS1794Unraveling the myelofibrotic bone marrow niche: Stromal and immune interactions as potential therapeutic targetsMartina CrysandtSaturday, June 1418:30–19:30
PS1818Molecular determinants of resistance to ropeginterferon alfa-2b in PV and ETJihyun SongSaturday, June 1418:30–19:30
PS1802Germline variants in myeloproliferative neoplasms with early onset or familial historyElisa RumiSaturday, June 1418:30–19:30
PS1829Impact of dual spleen response and transfusion independence on survival in JAK inhibitor-naive patients with myelofibrosis and anemia treated with momelotinib: A subgroup analysis of SIMPLIFY-1Francesca PalandriSaturday, June 1418:30–19:30

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

EHA 2025Polycythemia veraRuxolitinibEssential thrombocytosisPacritinibMomelotinibFedratinibMyelofibrosis

Newsletter

Subscribe to get the best content delivered to your inbox